Citations 2
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma
Forero‐Torres, Andres , Sher, Taimur , Diefenbach, Catherine , Johnston, Patrick B. , Talpaz, Moshe , Pulini, Jennifer, Zhou, Li , Scherle, Peggy , Chen, Xuejun , Phillips, Tycel , Barr, Paul M. , Talpaz, Moshe , Diefenbach, Catherine S
Blood | April 25, 2018 | Volume: 132 | Issue: 3 | Pages: 293-306
Key PointsINCB040093 was active across lymphoma subtypes, and the addition of itacitinib provided substantial activity in classic Hodgkin lymphoma. INCB040093 ± itacitinib had a manageable safety and tolerability profile; severe hepatic adverse effects were less common with the combination.
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)
Loh, Mignon L. , Brown, Patrick A. , Magoon, Daniel, Chen, Xuejun , Ahern, Charlotte H., Weigel, Brenda J. , Blaney, Susan M. , Reid, Joel M. , Tasian, Sarah K. , Rabin, Karen R. , Loh, Mignon L
Pediatric Blood & Cancer | May 13, 2015 | Volume: 62 | Issue: 10 | Pages: 1717-1724